With the advance of precision medicine and personalized treatments, targeted therapy of NSCLC plays an increasingly important role as a rising star and was demonstrated to effectively improve the survival prognosis of lung adenocarcinoma patients with EGFR gene mutations (3). This evidence concerns the gene EGFR and lung adenocarcinoma.